Rituximab (R)

DRUG14 trials

Sponsors

National Cancer Institute (NCI), Hoffmann-La Roche, The Lymphoma Academic Research Organisation, InnoCare Pharma Inc., Institute of Hematology & Blood Diseases Hospital, China

Conditions

B-Cell LymphomaDiffuse Large B-cell LymphomaDouble Expressor DLBCLGranulomatosis With PolyangiitisLymphoma, Mantle CellMantle Cell LymphomaMantle Cell Lymphoma (MCL)Marginal Zone Lymphoma

Phase 1

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

CompletedNCT03467373

Hoffmann-La RocheB-Cell Lymphoma, Non-Hodgkin Lymphoma

Start: 2018-03-13End: 2024-12-02Updated: 2025-01-17

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

RecruitingNCT06351527

InnoCare Pharma Inc.Mature B-cell Malignancies

Start: 2024-04-23End: 2027-10-25Target: 78Updated: 2025-06-19

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

RecruitingNCT06594640

Institute of Hematology & Blood Diseases Hospital, ChinaDiffuse Large B-cell Lymphoma

Start: 2024-05-30End: 2027-07-30Target: 108Updated: 2025-05-14

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

Not yet recruitingNCT07415980

Sun Yat-sen UniversityDouble Expressor DLBCL

Start: 2026-04-01End: 2031-04-01Target: 68Updated: 2026-02-17

Phase 2

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

CompletedNCT00114738

National Cancer Institute (NCI)Lymphoma, Mantle Cell, Mantle Cell Lymphoma

Start: 2005-06-15End: 2022-08-11Updated: 2022-10-10

ZR-MTX for PIOL Phase II Trial

Not yet recruitingNCT06973811

Peking Union Medical College HospitalPrimary Intraocular Lymphoma

Start: 2025-05-10End: 2029-10-30Target: 47Updated: 2025-05-20

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

Not yet recruitingNCT07185373

Huashan HospitalPrimary Central Nervous System Lymphoma

Start: 2025-10-01End: 2029-07-30Target: 215Updated: 2025-09-22

Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment

RecruitingNCT07199296

Ruijin HospitalMantle Cell Lymphoma (MCL)

Start: 2025-07-01End: 2028-07-01Target: 45Updated: 2025-09-30

Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

Active, not recruitingNCT07247383

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityMarginal Zone Lymphoma(MZL), Marginal Zone Lymphoma of Ocular Adnexal

Start: 2025-09-19End: 2028-12-31Target: 39Updated: 2025-11-25

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

RecruitingNCT07272499

Ruijin HospitalMantle Cell Lymphoma (MCL)

Start: 2025-09-10End: 2028-09-10Target: 25Updated: 2025-12-09

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

RecruitingNCT07410520

The First Affiliated Hospital with Nanjing Medical UniversityPrimary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)

Start: 2026-02-07End: 2029-12-31Target: 50Updated: 2026-02-13

Phase 3

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

RecruitingNCT06006117

The Lymphoma Academic Research OrganisationMarginal Zone Lymphoma

Start: 2023-09-05End: 2032-09-30Target: 260Updated: 2025-12-19

Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)

RecruitingNCT06983821

Ottawa Hospital Research InstituteGranulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)

Start: 2025-11-10End: 2029-02-01Target: 36Updated: 2026-01-30

Phase 4

Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

Not yet recruitingNCT07010302

Massachusetts General HospitalNMOSD

Start: 2026-05-01End: 2030-05-01Target: 540Updated: 2026-03-16

Related Papers

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Blood2025-11-03

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

2025-10-012 citations

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Blood2024-11-0513 citations

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Blood2023-11-0224 citations

Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.

Journal of Clinical Oncology2023-06-0120 citations

Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study

Hematological Oncology2023-06-011 citations

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Blood2022-11-1523 citations

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma

Blood Advances2022-02-1039 citations

Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study

Blood2021-11-0512 citations

Circulating tumor DNA to predict timing of relapse in mantle cell lymphoma.

Journal of Clinical Oncology2018-05-207 citations

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Blood2013-08-12204 citations